Gyre Therapeutics (GYRE) Prepaid Assets (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Prepaid Assets of $3.8 million for Q1 2026, down 53.9% year-over-year from $8.2 million in Q1 2025, and up 33.07% quarter-over-quarter from $2.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Prepaid Assets (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Prepaid Assets for 17 consecutive years, with $3.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 53.9% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (down 53.9% YoY), while the FY2025 annual figure was $2.8 million, up 137.76% from the prior year.
- Prepaid Assets rose to $3.8 million in Q1 2026 per GYRE's latest filing, from $2.8 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $8.2 million in Q1 2025 and bottomed at $697000.0 in Q2 2023.
- Historically, Prepaid Assets has averaged $2.1 million across 5 years, with a median of $1.3 million in 2022.
- Annual changes were most pronounced in 2022 — Prepaid Assets plunged 89.03% — and 2025, when it soared 355.92%.
- Gyre Therapeutics' Prepaid Assets stood at $843000.0 in 2022, then grew by 23.96% to $1.0 million in 2023, then gained by 13.78% to $1.2 million in 2024, then soared by 137.76% to $2.8 million in 2025, then jumped by 33.07% to $3.8 million in 2026.
- Business Quant data shows GYRE's Prepaid Assets at $3.8 million in Q1 2026, $2.8 million in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.60 Mn |
| Mar 31, 2026 | 3.76 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Sep 30, 2025 | 2.87 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 8.16 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 1.17 Mn |
| Jun 30, 2023 | 697,000.00 |
| Mar 31, 2023 | 915,000.00 |
| Dec 31, 2022 | 843,000.00 |
| Sep 30, 2022 | 2.16 Mn |
| Jun 30, 2022 | 914,000.00 |
| Mar 31, 2022 | 1.32 Mn |
| Dec 31, 2021 | 2.81 Mn |
| Sep 30, 2021 | 8.32 Mn |